Theravance Inc news

   Watch this stock
Showing stories 1 - 10 of about 104   

Articles published

THRX 13.82 0.00 (0.00%)
price chart
Theravance, Inc. Appoints Michael Faerm as Chief Business Officer
Theravance, Inc. is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals.
Theravance, Inc. Short Interest Update
Theravance, Inc. (NASDAQ:THRX), According to the latest information the short interest in Theravance, Inc. shot up by 2.6% or 690,589 shares. The final shorts are 33.5% of the total floated shares. The positions increased from 26,190,729 shares on July ...
Large Outflow of Money Witnessed in Theravance, Inc.
Theravance, Inc. (NASDAQ:THRX) managed to stay afloat and traded higher with an addition of 0.31 point or 2.33% at $13.59.
Shares of Theravance, Inc. (NASDAQ:THRX) Drops by -1.09%  Insider Trading Report
Zacks Short Term Rating on Theravance, Inc. (NASDAQ:THRX)  OTC Outlook
Theravance, Inc. (NASDAQ:THRX) Price Target Update
Theravance, Inc. (NASDAQ:THRX): 4 Analyst have given the stock of Theravance, Inc. (NASDAQ:THRX) a near short term price target of $14.
Dividend Stock Focus: Theravance, Inc. (NASDAQ:THRX)  Equities Focus
Why Shares of Theravance Inc Sank 12% in July
Despite reporting a net loss, Theravance continued paying a generous dividend of $0.25 per share. The huge dividend and interest payments continue to take its toll on the company's cash balance, which once again dropped and now stands at $229 million.
Theravance, Inc. Analyst Rating Update
Analysts at Zacks have given a short term rating of hold on Theravance, Inc. (NASDAQ:THRX) with a rank of 3. The company has received an average rating of 3.26 from 5 brokerage firms.
Glaxosmithkline Plc Insider of Theravance Inc (NASDAQ:THRX) Just Picked up ...
The insider Glaxosmithkline Plc of Theravance Inc (NASDAQ:THRX) 13.65 +0.09 0.66% invested in 245,828 shares of the -listed company having a total value of $856.92 billion U.S Dollars based on a market price of $3485841.0 for each one share.
Theravance Inc.: Theravance Biopharma, Inc. Reports Second Quarter 2015 ...  The Wall Street Transcript
Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and ...  MarketWatch
Theravance, Inc. Price Target Update
Theravance, Inc. (NASDAQ:THRX): The mean estimate for the short term price target for Theravance, Inc.
Will Theravance, Inc. (NASDAQ:THRX) Surprise This Quarter?  Investor Newswire
Company Shares of Theravance, Inc. (NASDAQ:THRX) Drops by -3.78%
Theravance, Inc. (NASDAQ:THRX) has lost 3.78% during the past week and dropped 15.81% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 4.42%.
Inside Trading: James Tyree Unloaded 2438 Shares of Theravance Inc (NASDAQ:THRX)
James Tyree, director of Theravance Inc (NASDAQ:THRX) 13.02 -0.03 -0.23% is the insider, OctaFinance want to disclose transactions for.
Theravance Inc (THRX) Discloses Form 4 Insider Selling : James L Tyree Sells ...  Money Flow Index